Syncom Formulations (India) Ltd
SYNC

Syncom Formulations (India) Ltd (524470)

₹9.333.78%

Key Stats

₹8.91
Day's Price Range
₹9.38
₹5.76
52-Week Price Range
₹19.49
1 Month Return13.08 %
3 Month Return5.39 %
1 Year Return33.77 %

Company Financials

  • Quarterly
  • Annual
Value in ₹ crore

Peer Comparsion

PE
Rank 224
74.57
EPS
Rank 241
₹0.12
BVPS
Rank 289
₹1.5
Dividend Yield
Rank 88
1.02%
ROE
Rank 124
17.51%
Price To Book Ratio
Rank 193
5.99
Debt To Asset
Rank 213
0.34

Company Information

Incorporated as a private limited company in 1988 Syncom Formulations India was converted into a public limited company in Jun.92. The company set up a manufacturing facility at Palghar Thane to produce pharmaceutical formulations. Commercial production commenced in Apr.89. Promoters are Kedarmal Bankda Vijay Kumar Bankda and Ajay Kumar Bankda.In addition to pharmaceutical formulations in the form of tablets capsules liquids and dry powders the company also manufactures injectibles and ear/eye drops on a loan licence basis.In 1994 the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur Madhya Pradesh. The project which was financed through a public issue made in Jan.94 was completed in 1995.During the year 199798 the Company has further diversified into Ethical Operations by introducing the range of prescription formulations.During the year 199899 there has been huge expansion of installed capacity and production base. Further the company plans introduction of products in the generic OTC and Ethical Divisions. The export earnings have also registered a growth of more than 100.During the year 19992000 the company and its associates have received export orders worth Rs.700.00 lacs against advance payment and hence better turnover is expected during the year. The company presently exports goods to Guine Ghana Kenya Tanzania Nigeria in Africa Azberjan Nepal and Srilanka in Asia. The company has been approved as a supplier to Central ESI Hospitals and registration of defence services is in its final stages as a result of which will generate substantial sales volume. Keeping in view the shifting consumer preferenes for the use of herbal products the company is aggressively manufacturing and marketing its herbal products like Edicare Attom Megacaps Ecziguard and Yas antacid salt.
OrganisationSyncom Formulations (India) Ltd
HeadquartersMumbai
IndustryPharmaceuticals